WO2004018709A3 - Single nucleotide polymorphisms predicting adverse drug reactions and drug efficacy in cardiovascular disease - Google Patents

Single nucleotide polymorphisms predicting adverse drug reactions and drug efficacy in cardiovascular disease Download PDF

Info

Publication number
WO2004018709A3
WO2004018709A3 PCT/EP2003/009126 EP0309126W WO2004018709A3 WO 2004018709 A3 WO2004018709 A3 WO 2004018709A3 EP 0309126 W EP0309126 W EP 0309126W WO 2004018709 A3 WO2004018709 A3 WO 2004018709A3
Authority
WO
WIPO (PCT)
Prior art keywords
cardiovascular disease
human subject
provides
risk
determining whether
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/009126
Other languages
French (fr)
Other versions
WO2004018709A2 (en
Inventor
Stephan Schwers
Harald Kallabis
Udo Stropp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Priority to US10/525,278 priority Critical patent/US20070128597A1/en
Priority to AU2003266291A priority patent/AU2003266291A1/en
Priority to EP03792358A priority patent/EP1532277A2/en
Publication of WO2004018709A2 publication Critical patent/WO2004018709A2/en
Publication of WO2004018709A3 publication Critical patent/WO2004018709A3/en
Anticipated expiration legal-status Critical
Priority to US12/255,695 priority patent/US20090138204A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy or whether the human subject is a high or low responder or a good a or bad metabolizer of statins. The invention provides further diagnostic methods and kits including antibodies determining whether a human subject is at risk for a cardiovascular disease. Still further the invention provides polymorphic sequences and other genes.The present invention further relates to isolated polynucleotides encoding a phenotype associated (PA) gene polypeptide useful in methods to identify therapeutic agents and useful for preparation of a medicament to treat cardiovascular disease or influence drug response, the polynucleotide is selected from the group comprising: SEQ ID 1-168 with allelic variation as indicated in the sequences section contained in a functional surrounding like full length cDNA for PA gene polypeptide and with or without the PA gene promoter sequence.
PCT/EP2003/009126 2002-08-19 2003-08-18 Single nucleotide polymorphisms predicting adverse drug reactions and drug efficacy in cardiovascular disease Ceased WO2004018709A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US10/525,278 US20070128597A1 (en) 2002-08-19 2003-08-18 Single nucleotide polymorphisms sensitively predicting adverse drug reactions (adr) and drug efficacy
AU2003266291A AU2003266291A1 (en) 2002-08-19 2003-08-18 Single nucleotide polymorphisms predicting adverse drug reactions and drug efficacy in cardiovascular disease
EP03792358A EP1532277A2 (en) 2002-08-19 2003-08-18 Single nucleotide polymorphisms sensitively predicting adverse drug reactions (adr) and drug efficacy
US12/255,695 US20090138204A1 (en) 2002-08-19 2008-10-22 Single nucleotide polymorphisms sensitively predicting adverse drug reactions (ADR) and drug efficacy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02018158A EP1394267A1 (en) 2002-08-19 2002-08-19 Single nucleotide polymorphisms predictive for cardiovascular disease, adverse drug reactions, and drug efficacy
EP02018158.2 2002-08-19

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/255,695 Continuation US20090138204A1 (en) 2002-08-19 2008-10-22 Single nucleotide polymorphisms sensitively predicting adverse drug reactions (ADR) and drug efficacy

Publications (2)

Publication Number Publication Date
WO2004018709A2 WO2004018709A2 (en) 2004-03-04
WO2004018709A3 true WO2004018709A3 (en) 2004-10-28

Family

ID=31197801

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/009126 Ceased WO2004018709A2 (en) 2002-08-19 2003-08-18 Single nucleotide polymorphisms predicting adverse drug reactions and drug efficacy in cardiovascular disease

Country Status (4)

Country Link
US (2) US20070128597A1 (en)
EP (2) EP1394267A1 (en)
AU (1) AU2003266291A1 (en)
WO (1) WO2004018709A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2573945A1 (en) * 2004-07-16 2006-01-26 Bayer Healthcare Ag Single nucleotide polymorphisms as prognostic tool to diagnose adverse drug reactions (adr) and drug efficacy
CA2612859A1 (en) * 2005-06-23 2006-12-28 The University Of British Columbia Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy
EP1963523A2 (en) * 2005-12-22 2008-09-03 Siemens Medical Solutions Diagnostics GmbH Method for the prediction of adverse drug responses
GB0606954D0 (en) * 2006-04-06 2006-05-17 Randox Lab Ltd Method
CN101589309A (en) * 2006-11-17 2009-11-25 临床基因网络公司 Screening and treatment methods involving the genes GYPC, AGPAT3, AGL, PVRL2, HMGB3, HSDL2 and/or LDB2
US20100056608A1 (en) * 2006-11-17 2010-03-04 Clinical Gene Networks Ab Methods for screening and treatment involving the genes gypc, agpat3, agl, pvrl2, hmgb 3, hsdl2 and/or ldb2
US7883851B2 (en) * 2007-05-02 2011-02-08 Board Of Regents, The University Of Texas System Common allele on chromosome 9 associated with coronary heart disease
US20110237537A1 (en) * 2009-05-29 2011-09-29 Lombard Jay L Methods for assessment and treatment of mood disorders via single nucleotide polymorphisms analysis
EP2435586A4 (en) * 2009-05-29 2012-12-26 Genomind Llc Methods for assessment and treatment of depression via utilization of single nucleotide polymorphisms analysis
US8355927B2 (en) 2010-11-05 2013-01-15 Genomind, Llc Neuropsychiatric test reports
AR080022A1 (en) * 2010-01-26 2012-03-07 Pioneer Hi Bred Int SEQUENCES OF POLINUCLEOTIDES AND POLYPEPTIDES ASSOCIATED WITH THE TOLERANCE TO HERBICIDES
EP2405271A1 (en) * 2010-07-06 2012-01-11 Bio-Rad Innovations Markers of vulnerability of the atherosclerosis plaque
US9305267B2 (en) * 2012-01-10 2016-04-05 The Board Of Trustees Of The Leland Stanford Junior University Signal detection algorithms to identify drug effects and drug interactions
WO2014018375A1 (en) * 2012-07-23 2014-01-30 Xenon Pharmaceuticals Inc. Cyp8b1 and uses thereof in therapeutic and diagnostic methods
RU2612630C2 (en) * 2014-09-17 2017-03-09 Федеральное бюджетное учреждение науки "Центральный научно-исследовательский институт эпидемиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ЦНИИ Эпидемиологии Роспотребнадзора) Method for determination of individual genetic risk for ischemic stroke
WO2018094204A1 (en) * 2016-11-17 2018-05-24 Arivale, Inc. Determining relationships between risks for biological conditions and dynamic analytes
US11289178B2 (en) 2017-04-21 2022-03-29 International Business Machines Corporation Identifying chemical substructures associated with adverse drug reactions
US20210009711A1 (en) * 2018-03-14 2021-01-14 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
CN114317726A (en) * 2022-02-24 2022-04-12 杭州惠煜医疗科技有限公司 Gene marker for detecting amyotrophic lateral sclerosis, detection method and application
CN115851966B (en) * 2022-09-06 2023-11-10 华南农业大学 ApoD gene molecular marker related to chicken carcass traits and application

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045477A2 (en) * 1997-04-04 1998-10-15 Eurona Medical Ab Methods for assessing cardiovascular status and compositions for use thereof
WO1999002735A2 (en) * 1997-07-10 1999-01-21 Millennium Pharmaceuticals, Inc. Diagnostic assays and kits for body mass and cardiovascular disorders
WO1999014363A1 (en) * 1997-09-16 1999-03-25 Eurona Medical Ab Genetic polymorphisms in the microsomal triglyceride transfer protein promoter and uses thereof
WO2000022166A2 (en) * 1998-10-14 2000-04-20 Pyrosequencing Ab Genes for assessing cardiovascular status and compositions for use thereof
WO2000079003A1 (en) * 1999-06-22 2000-12-28 Astrazeneca Uk Limited Polymorphisms in the human hmg-coa reductase gene
WO2002059369A2 (en) * 2000-11-01 2002-08-01 University Of Medicine And Dentistry New Jersey Medical School Compositions and methods for the treatment of diseases related to faulty cholesterol regulation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045477A2 (en) * 1997-04-04 1998-10-15 Eurona Medical Ab Methods for assessing cardiovascular status and compositions for use thereof
WO1999002735A2 (en) * 1997-07-10 1999-01-21 Millennium Pharmaceuticals, Inc. Diagnostic assays and kits for body mass and cardiovascular disorders
WO1999014363A1 (en) * 1997-09-16 1999-03-25 Eurona Medical Ab Genetic polymorphisms in the microsomal triglyceride transfer protein promoter and uses thereof
WO2000022166A2 (en) * 1998-10-14 2000-04-20 Pyrosequencing Ab Genes for assessing cardiovascular status and compositions for use thereof
WO2000079003A1 (en) * 1999-06-22 2000-12-28 Astrazeneca Uk Limited Polymorphisms in the human hmg-coa reductase gene
WO2002059369A2 (en) * 2000-11-01 2002-08-01 University Of Medicine And Dentistry New Jersey Medical School Compositions and methods for the treatment of diseases related to faulty cholesterol regulation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BASSO FEDERICA ET AL: "Interleukin-6 -174G>C polymorphism and risk of coronary heart disease in West of Scotland Coronary Prevention Study (WOSCOPS).", ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, vol. 22, no. 4, April 2002 (2002-04-01), April, 2002, pages 599 - 604, XP002241155, ISSN: 1079-5642 *
PEDRO-BOTET JUAN ET AL: "Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner.", ATHEROSCLEROSIS, vol. 158, no. 1, September 2001 (2001-09-01), pages 183 - 193, XP002241156, ISSN: 0021-9150 *
PIRMOHAMED M ET AL: "Genetic susceptibility to adverse drug reactions", TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER TRENDS JOURNAL, CAMBRIDGE, GB, vol. 22, no. 6, 1 June 2001 (2001-06-01), pages 298 - 305, XP004241902, ISSN: 0165-6147 *
See also references of EP1532277A2 *
TURNER STEPHEN T ET AL: "Antihypertensive pharmacogenetics: Getting the right drug into the right patient.", JOURNAL OF HYPERTENSION, vol. 19, no. 1, January 2001 (2001-01-01), pages 1 - 11, XP002241062, ISSN: 0263-6352 *

Also Published As

Publication number Publication date
US20070128597A1 (en) 2007-06-07
WO2004018709A2 (en) 2004-03-04
EP1532277A2 (en) 2005-05-25
EP1394267A1 (en) 2004-03-03
AU2003266291A1 (en) 2004-03-11
US20090138204A1 (en) 2009-05-28
AU2003266291A8 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
WO2004018709A3 (en) Single nucleotide polymorphisms predicting adverse drug reactions and drug efficacy in cardiovascular disease
Mochizuki et al. Human PON2 gene at 7q21. 3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence
JP6099268B2 (en) Genetic polymorphism associated with myocardial infarction, detection method and use thereof
JP5111380B2 (en) Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and use thereof
WO2002061131A3 (en) Human single nucleotide polymorphisms
WO2003072813A3 (en) Single nucleotide polymorphisms predicting adverse drug reactions and medication efficacy
EP1223937A2 (en) Gene necessary for striatal function, uses thereof, and compounds for modulating same
WO2004018708A3 (en) Genetic polymorphisms sensitively predicting adverse drug reactions (adr) and drug efficacy
US20020160451A1 (en) Novel orphan receptors
AU773765B2 (en) Methods for treating or identifying a subject at risk for a neurological disease by determining the presence of variant GPIIIA and/or variant GPIIB allele
WO2003029486A3 (en) Single nucleotide polymorphisms predicting cardiovascular disease
WO2001018250A3 (en) Single nucleotide polymorphisms in genes
WO2003057911A3 (en) Single nucleotide polymorphisms predicting cardiovascular disease and medication efficacy
Jin et al. Characterization of the tissue-specific expression of the s100P gene which encodes an EF-hand Ca2+-binding protein
WO2003059946A3 (en) Genetic polymorphisms predicting cardiovascular disease and medication efficacy
US20070154935A1 (en) Human obesity susceptibility gene and uses thereof
US20090092964A1 (en) Methods for Individualizing Cardiovascular Disease Treatment Protocols Based on Beta-1 Adrenergic Receptor Haplotype
WO2007071382A3 (en) Method for the prediction of adverse drug responses to statins
EP2027284A2 (en) Use of adamts4 gene and protein polymorphisms
CN109414504B (en) Pharmaceutical or food composition and method for evaluating in vivo effect of active ingredient
WO2001009346A1 (en) Gene encoding novel adenylate kinase 3 (ak3)-like protein
EP1882044A1 (en) Use of a gip promoter polymorphism
WO2004067774A3 (en) Single nucleotide polymorphisms as predictive diagnostics for adverse drug reactions (adr) and drug efficacy
JP2004154120A5 (en)
HK1046360A1 (en) Gene encoding nade, p75ntr-associated cell death executor and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003792358

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003792358

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007128597

Country of ref document: US

Ref document number: 10525278

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 10525278

Country of ref document: US